The Gulf Survey on Anemia Management (GSAM 2005).
We conducted this study to determine the achievements of the current practice guidelines in the management of anemia in the Arabian Gulf Countries. The survey was designed as a retrospective, one day screening of adult patients with end-stage renal disease in six Arabian Gulf countries including Saudi Arabia, Kuwait, Bahrain, Oman, United Arab Emirates and Qatar. Data were collected on patients undergoing chronic dialysis. For random patient sampling, each participating center drew up an alphabetical list of all hemodialysis (HD) or peritoneal dialysis (PD) patients which were 18 years or older and selected every fourth patient on the list. A total of 563 patients from 18 centers were included in the survey. The most common cause of end-stage renal failure was diabetic nephropathy, closely followed by chronic glomerulonephritis. The majority of patients were treated by HD, with only 20% receiving PD. The mean (+/-SD) hemoglobin (Hgb) concentration was 115 +/- 15 g/L (median, 115 g/L; range, 61-159 g/L). The Hgb concentration was > or = 110 g/L in 28%, > or = 120 g/L in 38% and < 100 g/L in 16%. Information on their iron status was available for 97% of patients, ferritin levels were available for 97% and TSAT values for 67% were available. The mean serum ferritin concentration for the study patients was 503 +/- 406 ng/ml (median, 390 ng/ml; range, 20.0-2960 ng/ml); 90.5% had a serum ferritin concentration > 100 ng/ml. We conclude that the results of our study demonstrate anemia management in the Gulf countries which is comparable to the European Survey on Anemia Management 2003 (ESAM 2003). However, many patients still have not reached the current recommendation of anemia management.
Alsuwaida
Abdulkareem
A
Department of Nephrology, King Saud University, Riyadh, Saudi Arabia. alsuwaida@hotmail.com
Abdulkareem
Ali
A
Alwakeel
Jamal
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D001445:Bahrain / Q000453:epidemiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000097:blood; D007676:Kidney Failure, Chronic / Q000150:complications / Q000453:epidemiology / Q000628:therapy; D007730:Kuwait / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009850:Oman / Q000453:epidemiology; D011159:Population Surveillance; D011379:Prognosis; D011780:Qatar / Q000453:epidemiology; D006435:Renal Dialysis; D012189:Retrospective Studies; D012529:Saudi Arabia / Q000453:epidemiology; D014479:United Arab Emirates / Q000453:epidemiology
D006454:Hemoglobins; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron